Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bivalirudin in HIT/HITTS patients undergoing PCI
NCT00759083Phase 4Withdrawn
- Sponsor
- The Medicines Company
- Start
- Sep 2008
- Primary completion
- Sep 2009
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of bivalirudin in heparin-induced thrombocytopenia (HIT), sponsored by The Medicines Company. Planned start Sep 2008; status: withdrawn.
02
Drugs
bivalirudin
03
Conditions
heparin-induced thrombocytopenia (HIT)
Beyond the preview
Go deeper on NCT00759083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00759083.